Please try another search
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.
Name | Age | Since | Title |
---|---|---|---|
Constance Smith-Hicks | - | - | Member of Scientific Advisory Board |
Zachary Rome | 39 | 2019 | Director |
Reymundo Lozano | - | - | Member of Advisory Board |
Alice Mao | - | - | Member of Scientific Advisory Board |
Veronica Martinez Cerdeno | - | - | Member of Advisory Board |
Andrew J. Cutler | - | 2023 | Member of Scientific Advisory Board |
John F. Coelho | 54 | 2022 | Independent Director |
Charles J. Casamento | 78 | 2022 | Lead Independent Director |
Robert K. Naviaux | - | - | Member of Scientific Advisory Board |
Vladimir Maletic | - | 2023 | Member of Scientific Advisory Board |
Rakesh Jain | - | 2023 | Member of Scientific Advisory Board |
Robert Findling | - | 2023 | Member of Scientific Advisory Board |
Karen J. LaRochelle | 56 | 2020 | Independent Director |
Michael Aman | - | - | Member of Scientific Advisory Board |
Stefan K. F. Schwabe | 71 | 2022 | Member of Scientific Advisory Board |
Howard J. Weisman | 64 | 2020 | CEO & Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review